Docoh
Loading...

IONS Ionis Pharmaceuticals

188 patents

Page 2 of 10
APP
Utility
Selective Antisense Compounds and Uses Thereof
5 Aug 21
The present invention provides oligomeric compounds.
Punit P. Seth, Michael Oestergaard, Eric E. Swayze
Filed: 3 Sep 20
GRANT
Utility
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
3 Aug 21
The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target.
Charles Allerson, Balkrishen Bhat, Anne B. Eldrup, Muthiah Manoharan, Richard H. Griffey, Brenda F. Baker, Eric E. Swayze
Filed: 26 Feb 19
GRANT
Utility
Compounds and methods for reducing ATXN2 expression
3 Aug 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN2 RNA in a cell or animal, and in certain instances reducing the amount of Ataxin-2 protein in a cell or animal.
Paymaan Jafar-nejad
Filed: 25 Jul 19
APP
Utility
Compositions for Modulating C9ORF72 Expression
29 Jul 21
Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal.
Frank Rigo
Filed: 18 Sep 20
GRANT
Utility
Compositions and their uses directed to huntingtin
27 Jul 21
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal.
Susan M. Freier
Filed: 15 Apr 20
GRANT
Utility
Compositions and methods for modulation of IKBKAP splicing
20 Jul 21
The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the IKBKAP gene.
C. Frank Bennett, Frank Rigo, Adrian R. Krainer, Rahul Sinha
Filed: 24 May 19
APP
Utility
Compositions for Modulating Expression of C9ORF72 Antisense Transcript
15 Jul 21
Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors.
Frank Rigo
Filed: 27 Aug 20
GRANT
Utility
Methods of treating breast cancer
13 Jul 21
Provided herein are methods, compounds, and compositions for reducing expression of a MaTAR in an animal.
David L. Spector, Sarah Daniela Diermeier, Frank Rigo, C. Frank Bennett, Susan M. Freier, Gayatri Arun, Kung-Chi Chang
Filed: 5 Dec 16
APP
Utility
Compositions and Methods for Modulating Growth Hormone Receptor Expression
8 Jul 21
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
Filed: 4 Aug 20
GRANT
Utility
Modulation of prekallikrein (PKK) expression
6 Jul 21
Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression.
Susan M. Freier, Huynh-Hoa Bui
Filed: 7 Sep 18
APP
Utility
MODULATORS OF ENaC EXPRESSION
17 Jun 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting ENaC expression, which may be useful for treating, preventing, or ameliorating a disease associated with ENaC.
Jeffrey R. Crosby, Shuling Guo, Huynh-Hoa Bui, Andrew T. Watt, Susan M. Freier
Filed: 31 Oct 18
GRANT
Utility
Modulation of Lnc05 expression
15 Jun 21
Provided herein are methods, compounds, and compositions for reducing expression of Inc05 in a cell or individual.
Allen Tingjin Yu, David L. Spector, Frank Rigo, Susan M. Freier, Jan Bergmann, Carmen Berasain
Filed: 1 Dec 17
APP
Utility
Methods for Reducing C9ORF72 Expression
10 Jun 21
Provided are methods for reducing the amount or activity of C9ORF72 RNA, and in certain instances of reducing the amount of C9ORF72 protein, in an animal.
C. Frank Bennett, Frank Rigo, Don W. Cleveland, Jie Jiang, Qiang Zhu, Clotilde Lagier-Tourene
Filed: 23 Jul 20
APP
Utility
Conjugated Antisense Compounds for Use in Therapy
10 Jun 21
Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.
Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
Filed: 28 Jul 20
APP
Utility
Modulation of Factor 11 Expression
10 Jun 21
Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof.
Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
Filed: 29 Jul 20
APP
Utility
Methods of Modulating Antisense Activity
10 Jun 21
Disclosed herein are methods for increasing antisense activity by modulating translation.
Xue-hai Liang, Stanley T. Crooke
Filed: 16 Nov 18
GRANT
Utility
Compounds and methods for reducing FXI expression
1 Jun 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject.
Huynh-Hoa Bui
Filed: 6 Nov 20
APP
Utility
Modulators of EZH2 Expression
27 May 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting EZH2 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with EZH2.
Minji Jo, Youngsoo Kim, Robert MacLeod, Susan M. Freier
Filed: 11 Apr 19
GRANT
Utility
Allele specific modulators of P23H rhodopsin
25 May 21
The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject.
Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
Filed: 28 Aug 19
APP
Utility
Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
20 May 21
The present invention provides oligomeric compounds.
Susan M. Freier, Eric E. Swayze
Filed: 30 Jun 20
Patents are sorted by USPTO publication date, most recent first